Abstract
A growing understanding of the biology of renal cell carcinoma (RCC) has led to the development and US Food and Drug Administration approval of seven new molecular targeted agents over the past 7 years. Axitinib is a potent, selective, second-generation inhibitor of vascular endothelial growth factor receptors and the latest to join the armamentarium of drugs available for the treatment of metastatic RCC. Despite recent advances in the development of molecular targeted agents for metastatic RCC, the ideal sequencing of these agents remains unclear.
DOI
10.2147/btt.s25862
Publication Date
2013-02-01
Publication Title
Biologics: Targets and Therapy
Publisher
Informa UK Limited
ISSN
1177-5475
Embargo Period
2024-11-19
First Page
39
Last Page
39
Recommended Citation
Ansari, J., Hussain, S., Glaholm, J., & Ansari, A. (2013) 'Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma', Biologics: Targets and Therapy, , pp. 39-39. Informa UK Limited: Available at: https://doi.org/10.2147/btt.s25862
